Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines

Irinotecan is a topoisomerase-I (Top-I) inhibitor used for the treatment of colorectal cancer. DNA demethylating agents, including 5-azacytidine (5-aza), display synergistic antitumor activity with several chemotherapy drugs. 5-Aza may enhance irinotecan cytotoxicity by at least one of the following mechanisms: (a) Top-I promoter demethylation, (b) activation of genes involved in Top-I transcriptional regulation (p16 or Sp1), and (c) modulation of the cell cycle and apoptosis after DNA damage. The growth-inhibitory effects of SN38, the active metabolite of irinotecan, 5-aza, and their combinations, were studied in four colorectal cancer cell lines. The effects of treatments on cell cycle were analyzed by flow cytometry, and apoptosis was measured by fluorescence microscopy. Top-I, Sp1, and p53 expression modulated by 5-aza were measured by real-time PCR. Methylation of Top-I, p16, 14-3-3σ, and hMLH1 promoters before and after 5-aza treatment were measured by MethyLight PCR and DNA bisulfite sequencing. Low-dose 5-aza significantly enhanced the apoptotic effect of irinotecan in all colorectal cancer cells, whereas a synergistic cytotoxic effect was observed only in p53-mutated cells (HT29, SW620, and WiDr). This synergistic effect was significantly correlated with Top-I up-regulation by 5-aza, and coupled to p16 demethylation and Sp1 up-regulation. p16 demethylation was also associated with enhanced cell cycle arrest after irinotecan treatment. In contrast, 5-aza down-regulated Top-I expression in the p53 wild-type LS174T cells in a p53-dependent manner, thereby reducing SN38 cytotoxicity. In conclusion, 5-aza modulates Top-I expression by several mechanisms involving Sp1, p16, and p53. If confirmed in other models, these results suggest that p16 and p53 status affects the 5-aza–irinotecan interaction. [Mol Cancer Ther 2009;8(7):1964–73]

[1]  K. Bhakat,et al.  Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage , 2008, Nucleic acids research.

[2]  J. Issa.  DNA methylation as a therapeutic target in cancer. , 2008, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Boulesteix,et al.  Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features , 2007, Clinical Cancer Research.

[4]  J. Issa,et al.  Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines , 2007, Clinical Cancer Research.

[5]  O. Wildner,et al.  Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment , 2007, Cancer Gene Therapy.

[6]  G. Bossi,et al.  BASIC SCIENCE REVIEW , 2007 .

[7]  Milena Krajnovic,et al.  Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. , 2007, World journal of gastroenterology.

[8]  Kenichi Sugihara,et al.  Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15 , 2007, Annals of Surgical Oncology.

[9]  M. Yashiro,et al.  Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma , 2006, Cancer science.

[10]  C. Pérez-Plasencia,et al.  Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? , 2006, Molecular Cancer.

[11]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[12]  C. Guillemette,et al.  Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer , 2006, Clinical Cancer Research.

[13]  M. Zeitz,et al.  Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth , 2006, Oncogene.

[14]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[15]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[16]  P. Johnston,et al.  Role of genomic markers in colorectal cancer treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Hurt,et al.  Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. , 2005, Cancer research.

[19]  R. Pazdur,et al.  Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.

[20]  M. Paz,et al.  Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. , 2005, Human molecular genetics.

[21]  J. Wheeler.  Epigenetics, mismatch repair genes and colorectal cancer. , 2005, Annals of the Royal College of Surgeons of England.

[22]  D. Jäger,et al.  [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[23]  G. Schwartz,et al.  Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe , 2004, Cancer Research.

[24]  E. Giovannetti,et al.  Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines , 2004, Clinical Cancer Research.

[25]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[26]  E. Rubin,et al.  Mechanisms of resistance to topoisomerase I-targeting drugs , 2003, Oncogene.

[27]  L. Saltz,et al.  The camptothecins , 2003, The Lancet.

[28]  B. Iacopetta.  TP53 mutation in colorectal cancer , 2003, Human mutation.

[29]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[30]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[31]  K. Venkatasubbarao,et al.  Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. , 2001, Cancer research.

[32]  L. Liotta,et al.  Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. , 2001, Cancer research.

[33]  P. Catalano,et al.  c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. , 2001, Cancer research.

[34]  D. Jones,et al.  Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. , 2001, Molecular pharmacology.

[35]  Ook Joon Yoo,et al.  Methylation in the p53 Promoter Is a Supplementary Route to Breast Carcinogenesis: Correlation between CpG Methylation in the p53 Promoter and the Mutation of the p53 Gene in the Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma , 2001, Laboratory Investigation.

[36]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[37]  M. Brattain,et al.  Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency , 2000, Oncogene.

[38]  M. Toyota,et al.  Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. , 2000, Cancer research.

[39]  W. Bodmer,et al.  DNA mismatch repair genes and colorectal cancer , 2000, Gut.

[40]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[41]  I. Pogribny,et al.  Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. , 2000, Cancer research.

[42]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[43]  N. Hayward,et al.  Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. , 1998, Mutation research.

[44]  C. D. Edwards,et al.  p16INK4A Participates in a G1 Arrest Checkpoint in Response to DNA Damage , 1998, Molecular and Cellular Biology.

[45]  J. Yokota,et al.  p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors , 1997, Japanese journal of cancer research : Gann.

[46]  M. Fukuda,et al.  Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non‐small Cell Lung Carcinomas , 1997, Japanese journal of cancer research : Gann.

[47]  K. Kohno,et al.  Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. , 1996, Cancer research.

[48]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[49]  M. Klein,et al.  Structural characterization of the human DNA topoisomerase I gene promoter. , 1990, European journal of biochemistry.

[50]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[51]  Robert Tjian,et al.  Mechanism of transcriptional activation by Sp1: Evidence for coactivators , 1990, Cell.